John D. Diekman, PhD

Founding Partner

John D. Diekman, Ph.D. is a Founding Partner of 5AM Ventures. Dr. Diekman served as a Managing Partner from 2002-2015 and transitioned to Founding Partner in January 2016. Prior to founding 5AM in 2002, Dr. Diekman was a Founder and Managing Director of Bay City Capital, a life science investment firm. Previously Dr. Diekman was Chairman and CEO of Affymetrix, and Chairman and Managing Director of Affymax. Dr. Diekman currently serves as Chairman of IDEAYA as well as on the Boards of Igenica and Wildcat. Dr. Diekman was formerly Chairman of Ambrx (acquired by a Chinese consortium) and a Board Director of Calibrium (acquired by Novo Nordisk), Cellular Research (acquired by Becton Dickinson), Chemdex (IPO), Envoy (acquired by Takeda), Ingenuity (acquired by Qiagen), LJL BioSystems (IPO), Marcadia (acquired by Roche) and PhaseRx. He is a Charter Trustee of Princeton University and a former Trustee of The California Institute of Technology and of The Scripps Research Institute, where he served as Chairman. He serves on the Schaeffer Center for Health Policy and Economics Advisory Board at the University of Southern California. He is an Honorary Officer of the Order of Australia. Dr. Diekman received a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University. Dr. Diekman holds an Honorary Degree of Doctor of Laws from Monash University. Dr. Diekman is based in the San Francisco, CA office.